(Reuters) -Zymeworks said on Tuesday it will stop developing its experimental cancer drug after results from a trial showed the treatment was unlikely to meet the company’s goals as a standalone therapy.
The Vancouver-based company was testing the drug, ZW171, in an early-stage trial for patients with ovarian and non-small cell lung cancers.
“This is a disappointing outcome given the promising preclinical activity observed with ZW171,” said chief executive Kenneth Galbraith.
The drug was designed to target mesothelin, a protein found in several types of tumors, including those in the lungs, ovaries, and digestive system.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Krishna Chandra Eluri)
Comments